Company intelligence / Profile preview

ROKIT Healthcare

Ownership: Private
Development stage: Commercial

Overview

ROKIT Healthcare develops hyper-personalized regenerative medicine solutions using proprietary bioprinting technology. Its main focus includes skin regeneration to treat diabetic foot ulcers—offering alternatives to amputation or skin grafts—and broader applications in organ/tissue engineering and anti-aging. The company has commercialized aspects of its technology globally and holds at least sixteen patents related to tissue engineering, stem cells, and biomaterials.[1][2][3][4]

Therapeutic areas: OtherEndocrinologyCardiovascular
Modalities: 3D bioprinted tissues/organs (bio-fabrication)Stem cell-based therapies[4]Biomaterials[4]
Industry: Biotech

Drug pipeline

1 asset

DFURegen

Commercial

Indications: Diabetic foot ulcer

Beyond the preview

Go deeper on ROKIT Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ROKIT Healthcare.

Explore the full profile